Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1386 EVOLVE-106, a T cell engager with integrated CD2 costimulation targeting B7-H4, is a precision therapy for estrogen and Her2 receptor low breast cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.
